▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1198 by analyst upside · 2026-09-05
COGT
Cogent Biosciences, Inc.
Healthcare · Market Cap $6B · P/E 0x
ANALYST PRICE TARGET
+60.6%
implied upside to consensus target
Current Price $34.76
Consensus Target $55.82
Bull Target $62.0
Bear Target $45.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
8
Hold
1
Sell
0
52-Week Low $11.6
52-Week High $43.73
YTD Return +0.1%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.15
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $11.6
52-Week High $43.73
Current Price $34.76
Bear Target $45.0
Bull Target $62.0
● Now $34.76 ● Target $55.82
TRADING DATA
Avg Volume 2.3M
YTD Return +0.1%
Analyst Count 11
Consensus Buy
Upside to Target +60.6%
Last Updated 2026-09-05

ANALYST SUMMARY

Cogent Biosciences, Inc. (COGT) is currently trading at $34.76 with a Wall Street consensus price target of $55.82, implying potential upside of 60.6% over the next 12 months. 11 analysts currently cover COGT, with a consensus rating of Buy - 91% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $62.0, while the most cautious has a target of $45.0.

COGT operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 0.1% year-to-date and is currently trading near the upper end of its 52-week range of $11.6 – $43.73.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GRFS +39.3%
Grifols, S.A.
$5B · P/E 10.3x · Buy
PACS +38.8%
PACS Group, Inc.
$7B · P/E 24.9x · Buy
INDV +40.2%
Indivior Pharmaceuticals, Inc.
$4B · P/E 12.5x · Buy
ACAD +21.3%
ACADIA Pharmaceuticals Inc.
$5B · P/E 12.5x · Buy
HNGE +15.3%
Hinge Health, Inc.
$7B · P/E 11.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for COGT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler - Reiterated
Overweight → Overweight 2026-08-17 14% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-08-12 62% win rate (8 calls)
Wedbush reit
Outperform → Outperform 2026-05-29 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-06 31% win rate (48 calls)
Wedbush reit
Outperform → Outperform 2026-03-17 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-02-18 14% win rate (7 calls)
Wedbush reit
Outperform → Outperform 2026-01-21 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-01-06 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
19/30
Consensus clarity
20/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →